Pfizer Warning Letter Trips Up Sandoz/Momenta’s Expected Glatopa Launch

Sandoz/Momenta’s generic of Teva’s 40 mg Copaxone appeared imminent – until apparently unrelated FDA warning letter regarding contract manufacturer Pfizer’s McPherson, Kan., plant put review on hold.

FDA won’t approve a generic multiple sclerosis drug for months now that apparently unrelated quality issues at a contract manufacturer have triggered a warning letter from the agency.

Sandoz Inc. and Momenta Pharmaceuticals Inc. were well on their way to launching the first generic competitor to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance